These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24520093)

  • 61. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
    Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
    Front Immunol; 2020; 11():1147. PubMed ID: 32582212
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant.
    Marques RF; Gimenez AM; Caballero O; Simpson A; Salazar AM; Amino R; Godin S; Gazzinelli RT; Soares IS
    Vaccine; 2024 Apr; 42(9):2394-2406. PubMed ID: 38448321
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
    Kyi C; Roudko V; Sabado R; Saenger Y; Loging W; Mandeli J; Thin TH; Lehrer D; Donovan M; Posner M; Misiukiewicz K; Greenbaum B; Salazar A; Friedlander P; Bhardwaj N
    Clin Cancer Res; 2018 Oct; 24(20):4937-4948. PubMed ID: 29950349
    [No Abstract]   [Full Text] [Related]  

  • 65. A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.
    McQuade JL; Homsi J; Torres-Cabala CA; Bassett R; Popuri RM; James ML; Vence LM; Hwu WJ
    BMC Cancer; 2018 Dec; 18(1):1274. PubMed ID: 30567529
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.
    Meehan KR; Talebian L; Tosteson TD; Hill JM; Szczepiorkowski Z; Sentman CL; Ernstoff MS
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):129-37. PubMed ID: 22975165
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.
    Fontana R; Bregni M; Cipponi A; Raccosta L; Rainelli C; Maggioni D; Lunghi F; Ciceri F; Mukenge S; Doglioni C; Colau D; Coulie PG; Bordignon C; Traversari C; Russo V
    Blood; 2009 Feb; 113(8):1651-60. PubMed ID: 19074732
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene.
    Lin L; Wei J; Chen Y; Huang A; Li KK; Zhang W
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):281-9. PubMed ID: 24322180
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
    Russo V; Pilla L; Lunghi F; Crocchiolo R; Greco R; Ciceri F; Maggioni D; Fontana R; Mukenge S; Rivoltini L; Rigamonti G; Mercuri SR; Nicoletti R; Maschio AD; Gianolli L; Fazio F; Marchianò A; Florio AD; Maio M; Salomoni M; Gallo-Stampino C; Fiacco MD; Lambiase A; Coulie PG; Patuzzo R; Parmiani G; Traversari C; Bordignon C; Santinami M; Bregni M
    Int J Cancer; 2013 Jun; 132(11):2557-66. PubMed ID: 23151995
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
    Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
    Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.
    Zsiros E; Duttagupta P; Dangaj D; Li H; Frank R; Garrabrant T; Hagemann IS; Levine BL; June CH; Zhang L; Wang E; Marincola FM; Bedognetti D; Powell DJ; Tanyi J; Feldman MD; Kandalaft LE; Coukos G
    Clin Cancer Res; 2015 Jun; 21(12):2840-50. PubMed ID: 25712684
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
    Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10
    Blumenschein GR; Devarakonda S; Johnson M; Moreno V; Gainor J; Edelman MJ; Heymach JV; Govindan R; Bachier C; Doger de Spéville B; Frigault MJ; Olszanski AJ; Lam VK; Hyland N; Navenot JM; Fayngerts S; Wolchinsky Z; Broad R; Batrakou D; Pentony MM; Sanderson JP; Gerry A; Marks D; Bai J; Holdich T; Norry E; Fracasso PM
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086946
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens.
    Liu X; Song N; Liu Y; Liu Y; Li J; Ding J; Tong Z
    Cell Immunol; 2015 Jun; 295(2):77-82. PubMed ID: 25863743
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs.
    Ammi R; De Waele J; Willemen Y; Van Brussel I; Schrijvers DM; Lion E; Smits EL
    Pharmacol Ther; 2015 Feb; 146():120-31. PubMed ID: 25281915
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
    Moreno-Bost A; Szmania S; Stone K; Garg T; Hoerring A; Szymonifka J; Shaughnessy J; Barlogie B; Prentice HG; van Rhee F
    Cytotherapy; 2011 May; 13(5):618-28. PubMed ID: 21171821
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial.
    Salazar AM; Erlich RB; Mark A; Bhardwaj N; Herberman RB
    Cancer Immunol Res; 2014 Aug; 2(8):720-4. PubMed ID: 24801836
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cellular immunotherapy for plasma cell myeloma.
    Garfall AL; Vogl DT; Weiss BM; Stadtmauer EA
    Bone Marrow Transplant; 2013 Nov; 48(11):1377-86. PubMed ID: 23645169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.